Dokument: Interventioneller Aortenklappenersatz bei hochgradiger Aortenklappenstenose und pulmonaler Hypertonie –Bedeutung des Zugangswegs
| Titel: | Interventioneller Aortenklappenersatz bei hochgradiger Aortenklappenstenose und pulmonaler Hypertonie –Bedeutung des Zugangswegs | |||||||
| Weiterer Titel: | Interventional aortic valve implantation in severe aortic stenosis and pulmonary hypertension-The importance of access site | |||||||
| URL für Lesezeichen: | https://docserv.uni-duesseldorf.de/servlets/DocumentServlet?id=51688 | |||||||
| URN (NBN): | urn:nbn:de:hbz:061-20191203-131223-4 | |||||||
| Kollektion: | Dissertationen | |||||||
| Sprache: | Deutsch | |||||||
| Dokumententyp: | Wissenschaftliche Abschlussarbeiten » Dissertation | |||||||
| Medientyp: | Text | |||||||
| Autor: | Papadopoulos, Georgios [Autor] | |||||||
| Dateien: |
| |||||||
| Beitragende: | Dr. Zeus, Tobias [Gutachter] Prof. Dr. med. Fenk, Roland [Gutachter] | |||||||
| Stichwörter: | TAVI, pulmonale Hypertonie | |||||||
| Dewey Dezimal-Klassifikation: | 600 Technik, Medizin, angewandte Wissenschaften » 610 Medizin und Gesundheit | |||||||
| Beschreibungen: | Zusammenfassung
Der interventionelle Aortenklappenersatz (TAVI: transcatheter aortic valve implantation) stellt bei Patienten mit symptomatischer hochgradiger Aortenklappenstenose mit erhöhtem perioperativem Risiko eine etablierte Behandlungsmethode dar. Eine zusätzlich bestehende pulmonale Hypertonie (PH) bei Patienten mit hochgradiger Aortenklappenstenose ist mit einem erhöhtem periinterventionellen Risiko und Mortalität assoziiert. TAVI kann als transarterieller Aortenklappenersatz (im wesentlichen transfemoraler Aortenklappenersatz: TF TAVI) ohne Narkose bzw. als transapikaler Aortenklappenersatz (TA TAVI) in Allgemeinnarkose und künstlicher Beatmung durchgeführt werden. Darüber hinaus erfordert der transapikale Aortenklappenersatz eine Minithorakotomie. Hypothese der Studie ist, dass die Koexistenz einer pulmonalen Hypertonie bei hochgradiger Aortenklappenstenose ein ungünstigerer Risikofaktor für das kurzfristige postinterventionelle Ergebnis ist und das die Häufigkeit der Komplikationen in Abhängigkeit von dem Zugangsweg variiert. Methodisch handelt es sich um eine monozentrische retrospektive Analyse einer existierenden Datenbank des Universitätsklinikums Düsseldorf unter Berücksichtigung von 795 Patienten aus den Jahren 2012-2016. Die Existenz einer PH wurde präinterventionell mittels einer Rechtsherzkatheteruntersuchung ermittelt. Klinische und laborchemische Patientencharakteristika wurden vor der Intervention analysiert. Primärer kombinierter Endpunkt war die 30-Tage Mortalität oder kardiopulmonaler Reanimation (CPR). Sekundäre Endpunkte der Studie waren die Krankenhaus- und Intensivstations-Verweildauer, Sepsis und Komplikationen nach VARC II Kriterien (Valve Academic Research Consortium-2). Dem Ergebnisse zufolge, beeinflusst die Existenz einer PH das kurzfristige Ergebnis nach TAVI negativ. Die Patienten mit PH und TA Zugang zeigten einen signifikanten Unterschied bezüglich unseres primären Endpunktes 30-Tage-Mortalität oder CPR. Unabhängig vom Zugangsweg waren die Patienten mit PH vulnerabler an einer akuten Niereninsuffizienz nach TAVI. Die Patienten ohne PH haben häufiger Blutungskomplikationen nach einer TA-TAVI gezeigt. Nach einer TF-TAVI haben die Patienten mit PH deutlich häufiger an einer postinterventionellen Sepsis gelitten. Zum Schluss zeigte sich die Krankenhaus- und Intensivstationsverweildauer signifikant länger bei den Patienten mit PH nach der Durchführung einer TF-TAVI. Zusammenfassend kommen wir zu dem Ergebnis, dass unabhängig vom Zugangsweg die Koexistenz einer präinterventionellen pulmonalen Hypertonie ein erhöhtes kurzfristiges postinterventionelles Risiko nach TAVI darstellen kann. Die Ausprägung des Risikos kann somit nach dem Zugangsweg differenziert werden. Die postinterventionellen Komplikationen sollten bekannt sein und durch ein proaktives periinterventionelles Management vermieden werden.Summary The interventional aortic valve implantation (TAVI: transcatheter aortic valve implantation) is a well-established method of treatment for patients with symptomatic severe aortic valve stenosis and increased perioperative risk. The coexistence of pulmonary hypertension (PH) in patients with severe aortic stenosis is associated with increased periinterventional risk and mortality. TAVI can either be performed as a transarterial aortic valve implantation (basically as a transfemoral aortic valve implantation: TF TAVI) without general anesthesia or as a transapical aortic valve implantation (TA TAVI) with need of general anesthesia and a minithoracotomy. The hypothesis of this study is that the coexistence of pulmonary hypertension in patients with severe aortic stenosis is a negative risk factor for the short term postinterventional outcome and that the frequency of complications varies according to the access point. Regarding the methodic aspects of the study, we performed a monocentric, retrospective analysis of an existing database of the university hospital of Düsseldorf under consideration of 795 patients between the years 2012-2016. The existence of PH was assessed preinterventionally through a right heart catheterization. Clinical and laboratory patient data where analyzed before the intervention. Our primary combined endpoint was the 30-day-mortality or cardiopulmonary resuscitation (CPR). Secondary endpoints of the study were the length of stay in hospital and intensive care unit (ICU), sepsis and complications according to the VARC II criteria (Valve Academic Research Consortium-2). The results showed that the existence of PH has a negative influence on the short-term outcome after a TAVI. Patients with PH and TA access showed a significant difference regarding our primary endpoint 30-day-mortality or CPR. Patients with PH were more vulnerable to an acute kidney injury after TAVI independent from the access point. Patients without PH had more often bleeding complications after a TA-TAVI. After performing a TF-TAVI, patients with PH showed more often a sepsis. To conclude, patients with PH had longer hospital and ICU-stay after a TF-TAVI. In summary, we showed that, independently from the access point, the preinterventional coexistence of PH increases the short-term postinterventional risk after TAVI. The gravity of this risk differs according to the access point. The postinterventional complications should be known and our proactive periinterventional management has to be adjusted to avoid them. | |||||||
| Quelle: | 1 Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: A population-based study. The Lancet. 2006;368(9540):1005-1011. doi:10.1016/S0140-6736(06)69208-8.
2 Iung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J. 2003;24(13):1231-1243. 3 Osnabrugge RLJ, Mylotte D, Head SJ, et al. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. J Am Coll Cardiol. 2013;62(11):1002-1012. doi:10.1016/j.jacc.2013.05.015. 4 Ramos J, Monteagudo JM, González-Alujas T, et al. Large-scale assessment of aortic stenosis: facing the next cardiac epidemic? Eur Heart J Cardiovasc Imaging. 2017. doi:10.1093/ehjci/jex223. 5 Chambers JB. Aortic stenosis. Eur J Echocardiogr. 2009;10(1):i11-9. doi:10.1093/ejechocard/jen240. 6 Boon A, Cheriex E, Lodder J, Kessels F. Cardiac valve calcification: Characteristics of patients with calcification of the mitral annulus or aortic valve. Heart. 1997;78(5):472-474. doi:10.1136/hrt.78.5.472. 7 Palta S, Pai AM, Gill KS, Pai RG. New insights into the progression of aortic stenosis: implications for secondary prevention. Circulation. 2000;101(21):2497-2502. 8 Kearney LG, Ord M, Buxton BF, et al. Progression of aortic stenosis in elderly patients over long-term follow up. Int J Cardiol. 2013;167(4):1226-1231. doi:10.1016/j.ijcard.2012.03.139. 9 Bonow RO, Carabello BA, Chatterjee K, et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;52(13):e1-142. doi:10.1016/j.jacc.2008.05.007. 10 Gerdts E. Left ventricular structure in different types of chronic pressure overload. European Heart Journal Supplements. 2008;10(suppl_E):E23-E30. doi:10.1093/eurheartj/sun015. 11 Lester SJ, Heilbron B, Gin K, Dodek A, Jue J. The Natural History and Rate of Progression of Aortic Stenosis. Chest. 1998;113(4):1109-1114. doi:10.1378/chest.113.4.1109. 12 Buck T, Breithardt O-A, Faber L, et al. Manual zur Indikation und Durchführung der Echokardiographie. Clin Res Cardiol Suppl. 2009;4(S1):3-51. doi:10.1007/s11789-009-0051-6. 13 Kuck K-H, Eggebrecht H, Elsässer A, et al. Qualitätskriterien zur Durchführung der kathetergestützten Aortenklappenimplantation (TAVI). Kardiologe. 2016;10(5):282-300. doi:10.1007/s12181-016-0082-4. 14 Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739-2791. doi:10.1093/eurheartj/ehx391. 15 Eggebrecht H, Mehta RH. Transcatheter aortic valve implantation (TAVI) in Germany 2008-2014: on its way to standard therapy for aortic valve stenosis in the elderly? EuroIntervention. 2016;11(9):1029-1033. doi:10.4244/EIJY15M09_11. 16 Rougé A, Huttin O, Aslam R, et al. Mid-term results of 150 TAVI comparing apical versus femoral approaches. J Cardiothorac Surg. 2015;10:147. doi:10.1186/s13019-015-0360-4. 17 Li X, Kong M, Jiang D, Dong A. Comparison 30-day clinical complications between transfemoral versus transapical aortic valve replacement for aortic stenosis: a meta-analysis review. J Cardiothorac Surg. 2013;8:168. doi:10.1186/1749-8090-8-168. 18 Schymik G, Wurth A, Bramlage P, et al. Long-term results of transapical versus transfemoral TAVI in a real world population of 1000 patients with severe symptomatic aortic stenosis. Circ Cardiovasc Interv. 2015;8(1). doi:10.1161/CIRCINTERVENTIONS.113.000761. 19 Galiè N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67-119. doi:10.1093/eurheartj/ehv317. 20 Aragam JR, Folland ED, Lapsley D, Sharma S, Khuri SF, Sharma G. Cause and impact of pulmonary hypertension in isolated aortic stenosis on operative mortality for aortic valve replacement in men. Am J Cardiol. 1992;69(16):1365-1367. doi:10.1016/0002-9149(92)91239-Z. 21 Faggiano P, Antonini-Canterin F, Ribichini F, et al. Pulmonary artery hypertension in adult patients with symptomatic valvular aortic stenosis. Am J Cardiol. 2000;85(2):204-208. 22 Johnson LW, Hapanowicz MB, Buonanno C, Bowser MA, Marvasti MA, Parker FB. Pulmonary hypertension in isolated aortic stenosis. Hemodynamic correlations and follow-up. J Thorac Cardiovasc Surg. 1988;95(4):603-607. 23 Silver K, Aurigemma G, Krendel S, Barry N, Ockene I, Alpert J. Pulmonary artery hypertension in severe aortic stenosis: Incidence and mechanism. Am Heart J. 1993;125(1):146-150. doi:10.1016/0002-8703(93)90067-J. 24 Rassi AN, Pibarot P, Elmariah S. Left ventricular remodelling in aortic stenosis. Can J Cardiol. 2014;30(9):1004-1011. doi:10.1016/j.cjca.2014.04.026. 25 O'Connor K, Magne J, Rosca M, Piérard LA, Lancellotti P. Left atrial function and remodelling in aortic stenosis. Eur J Echocardiogr. 2011;12(4):299-305. doi:10.1093/ejechocard/jer006. 26 JE Dalen, L Dexter, IS Ockene, J Carlson. Precapillary pulmonary hypertension: its relationship to pulmonary venous hypertension. Trans Am Clin Climatol Assoc;1974:pp. 207-218. http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2441359&blobtype=pdf. 27 Calin A, Mateescu AD, Rosca M, et al. Left atrial dysfunction as a determinant of pulmonary hypertension in patients with severe aortic stenosis and preserved left ventricular ejection fraction. Int J Cardiovasc Imaging. 2017;33(12):1939-1947. doi:10.1007/s10554-017-1211-2. 28 Ahn H-S, Chang S-A, Kim H-K, et al. Determinants of pulmonary hypertension development in moderate or severe aortic stenosis. Int J Cardiovasc Imaging. 2014;30(8):1519-1528. doi:10.1007/s10554-014-0498-5. 29 Lancellotti P, Magne J, Donal E, et al. Determinants and prognostic significance of exercise pulmonary hypertension in asymptomatic severe aortic stenosis. Circulation. 2012;126(7):851-859. doi:10.1161/CIRCULATIONAHA.111.088427. 30 Mutlak D, Aronson D, Carasso S, Lessick J, Reisner SA, Agmon Y. Frequency, determinants and outcome of pulmonary hypertension in patients with aortic valve stenosis. Am J Med Sci. 2012;343(5):397-401. doi:10.1097/MAJ.0b013e3182309431. 31 Roselli EE, Abdel Azim A, Houghtaling PL, Jaber WA, Blackstone EH. Pulmonary hypertension is associated with worse early and late outcomes after aortic valve replacement: implications for transcatheter aortic valve replacement. J Thorac Cardiovasc Surg. 2012;144(5):1067-1074.e2. doi:10.1016/j.jtcvs.2012.08.029. 32 Melby SJ, Moon MR, Lindman BR, Bailey MS, Hill LL, Damiano RJ. Impact of pulmonary hypertension on outcomes after aortic valve replacement for aortic valve stenosis. J Thorac Cardiovasc Surg. 2011;141(6):1424-1430. doi:10.1016/j.jtcvs.2011.02.028. 33 Gosain P, Larrauri-Reyes M, Mihos CG, Escolar E, Santana O. Aortic and/or mitral valve surgery in patients with pulmonary hypertension performed via a minimally invasive approach. Interact Cardiovasc Thorac Surg. 2016;22(5):668-670. doi:10.1093/icvts/ivw019. 34 Zlotnick DM, Ouellette ML, Malenka DJ, et al. Effect of preoperative pulmonary hypertension on outcomes in patients with severe aortic stenosis following surgical aortic valve replacement. Am J Cardiol. 2013;112(10):1635-1640. doi:10.1016/j.amjcard.2013.07.025. 35 Gutmann A, Kaier K, Reinecke H, et al. Impact of pulmonary hypertension on in-hospital outcome after surgical or transcatheter aortic valve replacement. EuroIntervention. 2017. doi:10.4244/EIJ-D-16-00927. 36 Magne J, Mohty D, Piccardo A, et al. Impact of Pulmonary Hypertension on Outcome in Patients with Severe Aortic Stenosis and Preserved Left Ventricular Ejection Fraction. Clin Res Cardiol. 2017;106(7):542-550. doi:10.1007/s00392-017-1085-2. 37 Schewel D, Schewel J, Martin J, et al. Impact of transcatheter aortic valve implantation (TAVI) on pulmonary hyper-tension and clinical outcome in patients with severe aortic valvular stenosis. Clin Res Cardiol. 2015;104(2):164-174. doi:10.1007/s00392-014-0772-5. 38 Barbash IM, Escarcega RO, Minha S, et al. Prevalence and impact of pulmonary hypertension on patients with aortic stenosis who underwent transcatheter aortic valve replacement. Am J Cardiol. 2015;115(10):1435-1442. doi:10.1016/j.amjcard.2015.02.022. 39 Luçon A, Oger E, Bedossa M, et al. Prognostic implications of pulmonary hypertension in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation: study from the FRANCE 2 Registry. Circ Cardiovasc Interv. 2014;7(2):240-247. doi:10.1161/CIRCINTERVENTIONS.113.000482. 40 Ruparelia N, Latib A, Buzzatti N, et al. Long-Term Outcomes After Transcatheter Aortic Valve Implantation from a Single High-Volume Center (The Milan Experience). Am J Cardiol. 2016;117(5):813-819. doi:10.1016/j.amjcard.2015.12.014. 41 D'Ascenzo F, Conrotto F, Salizzoni S, et al. Incidence, predictors, and impact on prognosis of systolic pulmonary artery pressure and its improvement after transcatheter aortic valve implantation: a multicenter registry. J Invasive Cardiol. 2015;27(2):114-119. 42 Tang M, Liu X, Lin C, et al. Meta-Analysis of Outcomes and Evolution of Pulmonary Hypertension Before and After Transcatheter Aortic Valve Implantation. Am J Cardiol. 2017;119(1):91-99. doi:10.1016/j.amjcard.2016.09.015. 43 Hosseinian L. Pulmonary hypertension and noncardiac surgery: implications for the anesthesiologist. J Cardiothorac Vasc Anesth. 2014;28(4):1064-1074. doi:10.1053/j.jvca.2013.11.017. 44 Kennedy JLW, LaPar DJ, Kern JA, et al. Does the Society of Thoracic Surgeons risk score accurately predict operative mortality for patients with pulmonary hypertension? J Thorac Cardiovasc Surg. 2013;146(3):631-637. doi:10.1016/j.jtcvs.2012.07.055. 45 Roques F. The logistic EuroSCORE. Eur Heart J. 2003;24(9):882. doi:10.1016/S0195-668X(02)00799-6. 46 Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. 2003;29(4):530-538. doi:10.1007/s00134-003-1662-x. 47 Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). Eur J Cardiothorac Surg. 2012;42(5):S45-60. doi:10.1093/ejcts/ezs533. 48 Ehret C, Rossaint R, Foldenauer AC, et al. Is local anaesthesia a favourable approach for transcatheter aortic valve implantation? A systematic review and meta-analysis comparing local and general anaesthesia. BMJ Open. 2017;7(9):e016321. doi:10.1136/bmjopen-2017-016321. 49 Tsapenko MV, Tsapenko AV, Comfere TB, Mour GK, Mankad SV, Gajic O. Arterial pulmonary hypertension in noncardiac intensive care unit. Vasc Health Risk Manag. 2008;4(5):1043-1060. 50 Galiè N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46(4):903-975. doi:10.1183/13993003.01032-2015. 51 Barbash IM, Escarcega RO, Minha S, et al. Prevalence and impact of pulmonary hypertension on patients with aortic stenosis who underwent transcatheter aortic valve replacement. Am J Cardiol. 2015;115(10):1435-1442. doi:10.1016/j.amjcard.2015.02.022. 52 Czerwińska-Jelonkiewicz K, Michałowska I, Witkowski A, et al. Vascular complications after transcatheter aortic valve implantation (TAVI): risk and long-term results. J Thromb Thrombolysis. 2014;37(4):490-498. doi:10.1007/s11239-013-0996-7. 53 Lindman BR, Zajarias A, Maniar HS, et al. Risk stratification in patients with pulmonary hypertension undergoing transcatheter aortic valve replacement. Heart. 2015;101(20):1656-1664. doi:10.1136/heartjnl-2015-308001. 54 Diehl P, Aleker M, Helbing T, et al. Increased platelet, leukocyte and endothelial microparticles predict enhanced coagulation and vascular inflammation in pulmonary hypertension. J Thromb Thrombolysis. 2011;31(2):173-179. doi:10.1007/s11239-010-0507-z. 55 Hoeper MM, Sosada M, Fabel H. Plasma coagulation profiles in patients with severe primary pulmonary hypertension. Eur Respir J. 1998;12(6):1446-1449. 56 Tournier A, Wahl D, Chaouat A, et al. Calibrated automated thrombography demonstrates hypercoagulability in patients with idiopathic pulmonary arterial hypertension. Thromb Res. 2010;126(6):e418-22. doi:10.1016/j.thromres.2010.08.020. 57 Gargiulo G, Sannino A, Capodanno D, et al. Impact of postoperative acute kidney injury on clinical outcomes after transcatheter aortic valve implantation: A meta-analysis of 5,971 patients. Catheter Cardiovasc Interv. 2015;86(3):518-527. doi:10.1002/ccd.25867. 58 Liao Y-B, Deng X-X, Meng Y, et al. Predictors and outcome of acute kidney injury after transcatheter aortic valve implantation-- a systematic review and meta-analysis. EuroIntervention. 2016. doi:10.4244/EIJ-D-15-00254. 59 Munoz-Garcia AJ, Munoz-Garcia E, Jimenez-Navarro MF, et al. Clinical impact of acute kidney injury on short- and long-term outcomes after transcatheter aortic valve implantation with the CoreValve prosthesis. J Cardiol. 2015;66(1):46-49. doi:10.1016/j.jjcc.2014.09.009. 60 Schnabel RB, Seiffert M, Wilde S, et al. Kidney injury and mortality after transcatheter aortic valve implantation in a routine clinical cohort. Catheter Cardiovasc Interv. 2015;85(3):440-447. doi:10.1002/ccd.25588. 61 Voigtlander L, Schewel J, Martin J, et al. Impact of kidney function on mortality after transcatheter valve implantation in patients with severe aortic valvular stenosis. Int J Cardiol. 2015;178:275-281. doi:10.1016/j.ijcard.2014.10.172. 62 Barbanti M, Latib A, Sgroi C, et al. Acute kidney injury after transcatheter aortic valve implantation with self-expanding CoreValve prosthesis: results from a large multicentre Italian research project. EuroIntervention. 2014;10(1):133-140. doi:10.4244/EIJV10I1A20. 63 Barbanti M, Gulino S, Capranzano P, et al. Acute Kidney Injury With the RenalGuard System in Patients Undergoing Transcatheter Aortic Valve Replacement: The PROTECT-TAVI Trial (PROphylactic effecT of furosEmide-induCed diuresis with matched isotonic intravenous hydraTion in Transcatheter Aortic Valve Implantation). JACC Cardiovasc Interv. 2015;8(12):1595-1604. doi:10.1016/j.jcin.2015.07.012. 64 Alassar A, Roy D, Abdulkareem N, Valencia O, Brecker S, Jahangiri M. Acute kidney injury after transcatheter aortic valve implantation: incidence, risk factors, and prognostic effects. Innovations (Phila). 2012;7(6):389-393. doi:10.1097/IMI.0b013e3182814e43. 65 Saia F, Ciuca C, Taglieri N, et al. Acute kidney injury following transcatheter aortic valve implantation: incidence, predictors and clinical outcome. Int J Cardiol. 2013;168(2):1034-1040. doi:10.1016/j.ijcard.2012.10.029. 66 Scherner M, Wahlers T. Acute kidney injury after transcatheter aortic valve implantation. J Thorac Dis. 2015;7(9):1527-1535. doi:10.3978/j.issn.2072-1439.2015.06.14. 67 Chatani K, Abdel-Wahab M, Wubken-Kleinfeld N, et al. Acute kidney injury after transcatheter aortic valve implantation: Impact of contrast agents, predictive factors, and prognostic importance in 203 patients with long-term follow-up. J Cardiol. 2015;66(6):514-519. doi:10.1016/j.jjcc.2015.02.007. 68 Gebauer K, Diller G-P, Kaleschke G, et al. The risk of acute kidney injury and its impact on 30-day and long-term mortality after transcatheter aortic valve implantation. Int J Nephrol. 2012;2012:483748. doi:10.1155/2012/483748. 69 Aronson D. Cardiorenal syndrome in acute decompensated heart failure. Expert Rev Cardiovasc Ther. 2012;10(2):177-189. doi:10.1586/erc.11.193. 70 Fiksen-Olsen MJ, Strick DM, Hawley H, Romero JC. Renal effects of angiotensin II inhibition during increases in renal venous pressure. Hypertension. 1992;19(2 Suppl):II137-41. 71 Kastner PR, Hall JE, Guyton AC. Renal hemodynamic responses to increased renal venous pressure: role of angiotensin II. Am J Physiol. 1982;243(3):F260-4. doi:10.1152/ajprenal.1982.243.3.F260. 72 Nilsson L, Appel C-F, Hultkvist H, Vánky F. Evaluation of the Valve Academic Research Consortium-2 Criteria for Myocardial Infarction in Transcatheter Aortic Valve Implantation: A Prospective Observational Study. PLoS ONE. 2015;10(6):e0130423. doi:10.1371/journal.pone.0130423. 73 Werner N, Zeymer U, Schneider S, et al. Incidence and Clinical Impact of Stroke Complicating Transcatheter Aortic Valve Implantation: Results From the German TAVI Registry. Catheter Cardiovasc Interv. 2016;88(4):644-653. doi:10.1002/ccd.26612. 74 Ledwoch J, Franke J, Gerckens U, et al. Incidence and predictors of permanent pacemaker implantation following transcatheter aortic valve implantation: analysis from the German transcatheter aortic valve interventions registry. Catheter Cardiovasc Interv. 2013;82(4):E569-77. doi:10.1002/ccd.24915. 75 Ferreira ND, Caeiro D, Adão L, et al. Incidence and predictors of permanent pacemaker requirement after transcatheter aortic valve implantation with a self-expanding bioprosthesis. Pacing Clin Electrophysiol. 2010;33(11):1364-1372. doi:10.1111/j.1540-8159.2010.02870.x. 76 Petronio AS, Sinning J-M, van Mieghem N, et al. Optimal Implantation Depth and Adherence to Guidelines on Permanent Pacing to Improve the Results of Transcatheter Aortic Valve Replacement With the Medtronic CoreValve System: The CoreValve Prospective, International, Post-Market ADVANCE-II Study. JACC Cardiovasc Interv. 2015;8(6):837-846. doi:10.1016/j.jcin.2015.02.005. 77 Lenders GD, Collas V, Hernandez JM, et al. Depth of valve implantation, conduction disturbances and pacemaker implantation with CoreValve and CoreValve Accutrak system for Transcatheter Aortic Valve Implantation, a multi-center study. Int J Cardiol. 2014;176(3):771-775. doi:10.1016/j.ijcard.2014.07.092. 78 Kaneko H, Hoelschermann F, Seifert M, et al. Predictors of permanent pacemaker implantation after transcatheter aortic valve implantation for aortic stenosis using Medtronic new generation self-expanding CoreValve Evolut R. Heart Vessels. 2018. doi:10.1007/s00380-018-1236-z. 79 Cuttica MJ, Kalhan R, Shlobin OA, et al. Categorization and impact of pulmonary hypertension in patients with advanced COPD. Respir Med. 2010;104(12):1877-1882. doi:10.1016/j.rmed.2010.05.009. | |||||||
| Lizenz: |  Urheberrechtsschutz | |||||||
| Fachbereich / Einrichtung: | Medizinische Fakultät | |||||||
| Dokument erstellt am: | 03.12.2019 | |||||||
| Dateien geändert am: | 03.12.2019 | |||||||
| Promotionsantrag am: | 19.02.2019 | |||||||
| Datum der Promotion: | 21.11.2019 |
